近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Wanting Hao#, Dongdong Luo#,*, Yuqi Jiang, Shengbiao Wan, Xiaoyang Li*. An overview of sphingosine-1-phosphate receptor 2: Structure, biological function, and small-molecule modulators. Med Res Rev. 2024, 44(5):2331-2362.
Enqiang Liu#, Yuxin Chen#, Mengting Qin#, Kairui Yue, Simin Sun, Yuqi Jiang, and Xiaoyang Li*. Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia. Eur J Med Chem. 2024, 276:116663.
Kairui Yue#, Simin Sun#, Enqiang Liu, Jinyu Liu, Baogeng Hou, Kangjing Qi, C. James Chou, Yuqi Jiang*, and Xiaoyang Li*. HDAC/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells. Eur J Med Chem,2024, 266:116127.
Geng Jia#, Jinyu Liu#, Xinlu Hou#, Yuqi Jiang*, and Xiaoyang Li*. Biological function and small molecule inhibitors of histone deacetylase 11. Eur J Med Chem. 2024, 276:116634.
Chao Huang#, Jinyu Liu#, Yuxin Chen, Simin Sun, Tongtong Kang, Yuqi Jiang*, and Xiaoyang Li*. Discovery of novel biphenyl-sulfonamide analogues as NLRP3 inflammasome inhibitors. Bioorg Chem. 2024, 146:107263.
Wanting Hao#, Leyan Wang#, Tongqiang Xu, Geng Jia, Yuqi Jiang, Chong Qin, and Xiaoyang Li*. Marine Cytotoxin Santacruzamate A Derivatives as Potent HDAC1-3 Inhibitors and Their Synergistic Anti-Leukemia Effects with Venetoclax. Mar. Drugs. 2024, 22: 250.
Simin Sun#, Zhuoyue Li#, Chao Huang#, Jinyu Liu, Qixin Yu, Xiaolin Jiang, Kairui Yue, Jianchun Zhao, Tongqiang Xu, Yankai Liu, Xiaoyang Li*, Chong Qin*, and Yuqi Jiang*. Discovery of Novel 2,3-Dihydro‑1H‑indene-5-sulfonamide NLRP3 Inflammasome Inhibitors Targeting Colon as a Potential Therapy for Colitis. J. Med. Chem. 2023, 66 (23):16141-16167.
Liang Zhang, Kangjing Qi, Jie Xu, Yan Xing, Xuejian Wang, Ling Tong, Zengguo He, Wenfang Xu, Xiaoyang Li*, and Yuqi Jiang*. Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine. J. Med. Chem. 2023, 66(6), 4150-4166.
Zhuoyue Li#, Yiming Chen#, Xiaolin Jiang#, Penghui Lu, Chengli Wang, Zhimin Li, Xinyue Yu, Zixuan Yang, Shumin Ma, Shanshan Du, Zhengfu Tai, Xiaoyang Li*, Siqi Zhang*, Yuqi Jiang*, and Chong Qin*. Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis. J. Med. Chem. 2023, 66 (18):12966-12989.
Jingjing Deng, Baogeng Hou, Xiaohan Hou, Yuxin Chen, Tao Zhang, Hua Chen, Yuanze Wang, and Xiaoyang Li*.Discovery of benzamide-based PI3K/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells. Eur J Med Chem. 2023, 262:115915.
Geng Jia#, Kangjing Qi#, Baogeng Hou, Kairui Yue, Tongqiang Xu, Yuqi Jiang*, and Xiaoyang Li*. Design, synthesis, and biological evaluation of novel HDAC/CD13 dual inhibitors for the treatment of cancer. Eur J Med Chem. 2023, 260:115752.
Jiangkun Yan, Kairui Yue, Xuejing Fan, Ximing Xu, Jing Wang, Mengting Qin, Qianer Zhang, Xiaohan Hou, Xiaoyang Li*, Yong Wang*. Synthesis and bioactivity evaluation of ferrocene-based hydroxamic acids as selective histone deacetylase 6 inhibitors. Eur J Med Chem, 2023, 246:115004.
Kairui Yue, Simin Sun, Geng Jia, Mengting Qin, Xiaohan Hou, C. James Chou, Chao Huang, and Xiaoyang Li*. First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation. J Med Chem.2022, 65(18):12140-12162.
Yuqi Jiang#, Jie Xu#, Kairui Yue#, Chao Huang, Mengting Qin, Dongyu Chi, Qixin Yu, Yue Zhu, Xiaohan Hou, Tongqiang Xu, Min Li, C. James Chou*, and Xiaoyang Li*. Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo. J Med Chem.2022,65(1):285-302
Dongdong Luo, Xiaochun Liu, Leilei Jiang, Zhikun Guo, Yan Lv, Xiaochen Tian, Xiaoyan Wang, Shuxiang Cui, Shengbiao Wan, Ximing Xu*, Xiaoyang Li*, and Xianjun Qu*. Rational Design, Synthesis and Biological Evaluation of Novel S1PR2 Antagonists for Reversing 5-FU-resistance in Colorectal Cancer. J Med Chem. 2022, 65(21),14553-14577.
Kairui Yue, Mengting Qin, Chao Huang, C James Chou, Yuqi Jiang, Xiaoyang Li*. Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study. Bioorg Med Chem Lett.2022, 70, 128797.
Kairui Yue, Chen Xu, Zhihao Wang, Wandong Liu, Chenyu Liu, Ximing Xu, Yan Xing, Sheng Chen*, Xiaoyang Li*, Shengbiao Wan*. 1,2-Isoselenazol-3(2H)-one derivatives as NDM-1 inhibitors displaying synergistic antimicrobial effects with meropenem on NDM-1 producing clinical isolates. . Bioorg Chem. 2022, 129, 106153.
Kairui Yue, Xiaohan Hou, Geng Jia, Liang Zhang, Jian Zhang, Leqiao Tan, Xuejian Wang, Zhaolin Zhang, Peixia Li, Wenfang Xu, Xiaoyang Li*, Yuqi Jiang*, Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy. . Bioorg Chem.2021, 116, 105343
Xiaoyang Li#*, Yuqi Jiang#, Yuri K. Peterson, Tongqiang Xu, Richard A. Himes, Xin Luo, Guilin Yin, Elizabeth S. Inks, Nathan Dolloff, Stephanie Halene, Sherine S. L. Chan, and C. James Chou*. Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity. J Med Chem. 2020,28; 63(10):5501-5525.
Xiaoyang Li*, Richard A. Himes, Lyndsey C. Prosser, Charleston F. Christie, Emma Watt, Sharon F. Edwards, Cameron Metcalf, Peter West, Karen Wilcox, Sherine S. L. Chan*, and C. James Chou*. Discovery of the first Vitamin K analog as a potential treatment of pharmacoresistant seizures. J Med Chem. 2020, 63(11):5865-5878.
京公网安备 11010802027423号